Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon's Immuno-oncology Models Evaluation Platform

2020-12-01
|
Page View:
Immuno-oncology Model

In recent years, tumor immunotherapy has become the core of cancer treatment research. With innovation as the driving force, Medicilon has vigorously developed a tumor immunity (Immuno-oncology) drug efficacy evaluation research platform. At present, CAR-T, TCR-T, CAR-NK, Oncolytic Virus, antibodies (monoclonal antibodies, double antibodies, polyclonal antibodies, etc.), siRNA, AAV and other immunotherapy models and methods for evaluating the efficacy of immunotherapy, empower the research process of innovative therapies and protect health!

Syngenic Models

The homologous tumor transplantation model tests the ability of model animals to use their perfect immune system to fight cancer and the therapeutic effect of immunotherapy.
The choices we offer you are:

Types of Syngenic Models
Types of Syngenic Models

Classification of immune cells in model blood by flow cytometry

PBMC Humanized Models

The humanized tumor mouse model of partially reorganized human immune system is particularly effective for short-term research or high-throughput research.
The types of models currently available for Medicilon are:

PBMC Humanized Models

Tumor growth and drug efficacy evaluation of PBMC humanized mouse lymphoma transplantation model

PBMC humanized mouse lymphoma transplantation model

CD34+ HSC Humanized Models

Humanized mice transplanted with CD34+ human umbilical cord blood cells to reconstruct the human hematopoietic system are colonized in the mouse bone marrow, and continuously and stably produce various human hematopoietic cells and immune cells, and use the human immune system to evaluate various immunotherapy.
Medicilon’s currently available models are:

CD34+ HSC Humanized Models

Orthotopic Model

The xenogeneic orthotopic tumor transplantation model can fully consider the interaction of tumor cells and the organ microenvironment between the surrounding stroma and monitor tumor growth when evaluating drug efficacy.

Medicilon will break the barriers of experimentation and technology for you. At present, it has mature orthotopic transplantation technology, including orthotopic brain transplantation, orthotopic liver transplantation, orthotopic lung transplantation, orthotopic transplantation of tibia marrow cavity, orthotopic intravesical transplantation Transplant etc.

Orthotopic brain transplantation

Orthotopic brain transplantation

Lung metastasis model

Lung metastasis model

Tibia bone marrow cavity orthotopic transplantation

Tibia bone marrow cavity orthotopic transplantation

Orthotopic ovarian cancer transplantation

Orthotopic ovarian cancer transplantation

PDX Models

The human tumor transplantation model PDX retains the characteristics of the patient’s tumor tissue and is more clinically relevant. Combined with humanized mice, it can establish an ideal tumor immunotherapy evaluation model.
Medicilon has now developed:

Medicilon’s PDX model research includes molecular level genotyping and tumor model pharmacological efficacy evaluation services, providing a highly predictive model for the study of clinical efficacy.

contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500

Related Articles:

Syngeneic Mouse Models

Return
Relevant newsRelevant news